Buyout deal looming, Novo Nordisk raids AstraZeneca for a new chief to run its struggling biopharma business
Fresh off the heels of an R&D reorganization announced last month, Danish drugmaker Novo Nordisk has appointed AstraZeneca’s Ludovic Helfgott as executive vice president of its fledgling biopharma business.
Helfgott is set to replace company veteran and former Novo CFO Jesper Brandgaard in April next year, who is retiring following a twenty-year stint with the Danish company best known for its raft of diabetes treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.